Language
Czechia

Interruption of marketing · 05.10.2026

Supply shortage Czechia: DESLORATADINE ACTAVIS 5MG TBL FLM 90

Affected country: Czechia · Reported period: 25.11.2026 – 31.03.2027 · Active ingredient: DESLORATADIN

Illustration of medicine supply and shortage monitoring in Europe – Supply shortage DESLORATADINE ACTAVIS 5MG TBL FLM 90 | PZN nicht angegeben
Illustration of medicine supply and shortage monitoring in Europe – Supply shortage DESLORATADINE ACTAVIS 5MG TBL FLM 90 | PZN nicht angegeben
CountryCzechia
PZNnicht angegeben
ENRSÚKL-Code 0168949
Notification typeInterruption of marketing
Start25.11.2026
Expected end31.03.2027
Last update05.10.2026
ReasonManufacturing reasons
ATCR06AX27
Hospital-relevantNo

Notice context

A supply shortage has been recorded for DESLORATADINE ACTAVIS 5MG TBL FLM 90 in Czechia. The stated reason is “Manufacturing reasons”. The notice concerns the active ingredient DESLORATADIN and is not identified as hospital-relevant.

This information describes the reported supply status and is not medical or pharmaceutical treatment advice. Availability, alternatives and further measures must be assessed for each individual case by the responsible pharmaceutical market participants.

Primary source: SÚKL Market Report

Official shortage notice for Czechia. Responsibility and update procedures follow the information supplied by the relevant authority.

Check the official notice list →

Implications for procurement and the supply chain

The notice for DESLORATADINE ACTAVIS 5MG TBL FLM 90 is a supply signal concerning DESLORATADIN in Czechia. The published reason “Manufacturing reasons” determines which data should be verified first.

For manufacturing or capacity constraints, the focus is on credible restart dates, available batches, qualified sources and the coverage of existing stock.

Decision route for this supply case

  1. Confirm the notice, product identity, period and actual demand with the primary source and accountable market participants.
  2. Assess restart timing, available batches, qualified sources and a lawful bridging stock separately.
  3. Document release, stock status, GDP evidence, warehousing and transport process, and escalation responsibility.

Inter-Pharma can structure the B2B case, potential sourcing and warehousing routes, and operational implementation. Clinical decisions, regulatory permissibility, product release and actual availability remain with the accountable parties.

Request a structured supply review →

Operational shortage resilience: GDP warehousing and pharmaceutical storage

For manufacturing shortages, an agreed restart stock for DESLORATADINE ACTAVIS 5MG TBL FLM 90 can be received and distributed under control after release.

Inter-Pharma combines GDP-oriented pharmaceutical storage in Czechia with batch and expiry control, FEFO, stock status, picking and dispatch preparation in its own Cheb operation.

Storage at 15–25 °C or any 2–8 °C requirement is derived solely from the product specification and confirmed for the project.

Operational checks for this notice

  • Match product identity using record SÚKL-Code 0168949, active ingredient, strength, dosage form and pack.
  • Confirm the reported status and the period 25.11.2026 to 31.03.2027 with the primary source and potential suppliers.
  • Document demand, stock coverage, open orders and lawful alternative or sourcing routes for the specific case.
  • Clarify temperature, batch, expiry, stock status, recipient authorisation and GDP evidence before cross-border supply.

Relevant services and specialist pages

The following B2B topics are particularly relevant when handling a shortage involving DESLORATADINE ACTAVIS 5MG TBL FLM 90:

Related topics